Extent and Management of Anaemia in Transplant Patients EDTNA/ERCA Anaemia&Transplant Interest Groups.

Slides:



Advertisements
Similar presentations
UK Renal Registry 13th Annual Report Figure 12.1: Median height z-scores for transplant patients in 2009.
Advertisements

A changing world ● Globalisation / Globalisations? Global trade (ESPON - Europe in the world – 2007)
Anemia in Transplantation Yvette Talusan- Tomacruz, M.D.
Turma 6 Bárbara Vieira, Diana Pires, Iolanda Vieira, João Novo, José Machado, Lia Rodrigues, Maria Lume, Mário Sousa, Mónica Pereira, Patrícia Gouveia,
Political Map of Europe. 1. British Isles 2. Nordic Nations 3. Central Western Europe 4. Mediterranean Europe 5. Eastern Europe.
Folke Sjöqvist and Michael Orme 1 Questionnaire on Clinical Pharmacology.
11-12 June 2009 Survey of the data sources and compilation practices of EU Member States Item 4.1 International Technical Meeting on Measuring Remittances.
A PureBase Global locality Inheritance from Europe Eugene Kunda Project manager Axioma TM LLC MORION.
Recent management of Renal Transplantation in a Developing Country like Bangladesh, R Alam, Islam M S, R Alam, H Rahman, HU Rashid Department of Nephrology,
UK Renal Registry 17th Annual Report Figure 9.1. Median height z-scores for transplant patients
UK Renal Registry 16th Annual Report Figure Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2012.
UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.
UK Renal Registry 17th Annual Report Figure 3.1. Transplant prevalence rate per million population by age and gender on 31/12/2013.
Knowledge Management LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
Institutional Visits IV KAM Prague, 3 rd to 7th September.
How to manage anaemia in HD patients
Elisabeth AUBENY, M.D. FIAPAC Broussais Hospital Paris - France The Western European experience of medical termination of early pregnancy.
ELSA Shop(ping) – Spring SALE! LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
Knowledge Management and Transition ICM Cluj-Napoca, 24th April 2015.
ELSA Shop(ping) LXIV International Council Meeting Opatija, Croatia October 28 th - November 3 rd 2013.
BWGHF Liège Heart transplantation 2008.
Eurotransplant: An example of success for cross-border cooperation Bruno Meiser Eurotransplant International Foundation, Leiden, Netherlands Dept. of Cardiac.
Area Definition III KAM,Bratislava. The European Law Students’ Association Albania ˙ Austria ˙ Azerbaijan ˙ Belgium ˙ Bosnia and Herzegovina ˙ Bulgaria.
UK Renal Registry 14th Annual Report Figure 3.1. Transplant prevalence rate per million population by age and gender on 31/12/2010.
UK Renal Registry 17th Annual Report Figure Percentage of patients waitlisted for a kidney transplant by renal centre, prior to or within two years.
Make it Smart&Creative ICM Cluj-Napoca, 21st April 2015.
Presenter: U. Rothe/ U. Manuwald Institution: 3 rd WP7 meeting Istituto Superiore di Sanità, Roma July, 2-3, 2015 Questionnaire on Prevention and Management.
Doing Business in Europe Bay Area CITD Seminar Series Tuesday, September 21st, 2004 Kemarra Inc. - Key Marketing Resources & Associates San Francisco USA.
UK Renal Registry 9 th Annual Report 2006 Fig 11.1 UK transplantation prevalence rate per million population by age and gender on 31/12/2005.
ICM Bodrum 24 th October AA Workshop Legal Research Group.
UK Renal Registry 10th Annual Report 2007 Fig 8.1 Median haemoglobin for incident dialysis patients at start of dialysis treatment.
Institutional Visit LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
Poland Czech Republic Slovakia Hungary Croatia Serbia Bosnia & Herzegovina Slovenia Montenegro Russia Atlantic Ocean Arctic Ocean Austria Netherlands Belgium.
ELSA as the Franchise? LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
Survival after graft failure Dr Lynsey Webb Registrar UK Renal Registry UK Renal Registry 2011 Annual Audit Meeting.
SPORTS MEDICINE SPECIALIZATION – 24 countries 1)Belarus 13)Romania 2) Bosnia & Herzegovina 14)Serbia 3) Bulgaria 15)Slovenia 4) Czech Republic 16)Spain.
UK Renal Registry 15th Annual Report Figure 6.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2011.
Integrated Multidisciplinary Management of Invasive Fungal Infections Dr. Murat Akova Hacettepe University School of Medicine Section of Infcetious Diseases.
Map - Region 3 Europe.
2010 HIV/AIDS surveillance in Europe European Centre for Disease Prevention and Control, Stockholm WHO Regional Office for Europe, Copenhagen.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 13: International Comparisons.
Social Studies: Europe & Russia Lesson 34 Practice & Review
Computer Class – Summer 20092/21/2016 3:45 AM European Countries Albania Andorra Austria Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Czech.
UK Renal Registry 16th Annual Report Figure Median height z-scores for transplant patients
Country EPS-12 Total (with ICPS) Hungary7979 Germany5559 Romania3841 Ukraine2527 United Kingdom1930 Finland1842 France1616 Italy1616 Poland1313 Switzerland1314.
The European Law Students’ Association Albania ˙ Austria ˙ Azerbaijan ˙ Belgium ˙ Bosnia and Herzegovina ˙ Bulgaria ˙ Croatia ˙ Cyprus ˙ Czech Republic.
What happens to patients returning to dialysis after transplant failure? Data from the UK Renal Registry Dr Lynsey Webb 1, Dr Anna Casula 1, Dr Charlie.
UK Renal Registry 15th Annual Report Figure 7.1. Median height z-scores for transplant patients
The use of Ferinject® (ferric carboxymaltase) in the treatment of iron deficiency in patients with renal anaemia Dr D Farrugia Dr S Ramakrishna E Gibson.
France Ireland Norway Sweden Finland Estonia Latvia Spain Portugal Belgium Netherlands Germany Switzerland Italy Czech Rep Slovakia Austria Poland Ukraine.
Best Sustainable Development Practices for Food Security UV-B radiation: A Specific Regulator of Plant Growth and Food Quality in a Changing Climate The.
Mansoura International Hospital Mansoura International Hospital
DISTRIBUTION AUTOMATIC - GENERATION
In complete sentences answer the following questions:
UK Renal Registry 15th Annual Report
Figure 1. Number of reported hantavirus infection cases, EU/EEA, 2014
Statistics on crime and criminal justice, Eurostat Working group meeting, 19–20 February 2009, Luxemburg Council of Europe Annual Penal Statistics – 2006.
Questionnaire on Clinical Pharmacology
Намалување на загадувањето на воздухот со електромобилност
European survey respondents by region.
EUROPEAN PERIOPERATIVE Safe Surgery Saves Lives
Adriatic Persian Gulf Map Test #1 Answers.
S. Sagedal, A. Hartmann, H. Rollag  Clinical Microbiology and Infection 
UK Renal Registry 13th Annual Report
Adriatic Persian Gulf Map Test #1 Answers.
European representation of respiratory critical care HERMES participants. European representation of respiratory critical care HERMES participants. Countries.
UK Renal Registry 10th Annual Report 2007
ODCs in a theoretical subject with anaemia and haemoglobin (Hb) concentration of 7.5 g ⋅ dL−1 compared to normal haemoglobin concentration of 15 g ⋅ dL−1.
UK Renal Registry 9th Annual Report 2006
Presentation transcript:

Extent and Management of Anaemia in Transplant Patients EDTNA/ERCA Anaemia&Transplant Interest Groups

TRESAM  38.6% anaemia during a 5 year post- transplant period  8.5% severe anaemia  Risk factors: renal function, ACEI/ARB, donor age, recent infection only 18.5% pts with severe anaemia treated with erythropoietin

USA Yorgin et al (2002)  26% anaemic at 5 years post-transplant  Renal function greatest risk factor  63% anaemic on switching from aza to MMF

 “Anemia, which is a treatable complication, is significantly and independently associated with mortality and graft failure in kidney- transplanted patients” Molnar et al 2007.AmJTranspl.7(4)

 European Best Practice Guidelines Hb >11g/dL

 PTA is common  Needs to be Managed  Monitor and evaluate reasons for anaemia  European Best Practice Guidelines

The Survey  Postal  English for UK, Netherlands, Belgium, Luxemburg; rest translated  Extent and management of PTA

Questions asked  What is the total number of dialysis patients in your centre?  Are transplants carried out at your centre?  How many transplant patients are followed up in your centre?  How many of these transplant patients currently use Epo?  Who monitors the full blood count in your transplant patients?  Is there an identified person with sole responsibility for monitoring anaemia in your transplant patients?  What percentage of your transplant patients have a haemoglobin < 11.0 g/dL?  What parameters do you use to determine the cause of anaemia in your transplant patients?  Does your centre specify a haemoglobin below which a transplant patient is normally started on Epo?  Do you have any specific algorithms / protocols to manage anaemia in your transplant patients?  What protocols do you have?  Would you find it useful to have a comprehensive algorithm?  Comments ?

centres responding in each country 13 countries Germany10 (26%) Germany10 (26%) Spain6 (15%) Spain6 (15%) Greece4 (10%) Greece4 (10%) Israel4 (10%) Israel4 (10%) Austria3 ( 8%) Austria3 ( 8%) UK3 ( 8%) UK3 ( 8%) Belgium2 ( 5%) Belgium2 ( 5%) Bosnia-Herzegovina2 ( 5%) Bosnia-Herzegovina2 ( 5%) Croatia1 ( 3%) Croatia1 ( 3%) Hungary1 ( 3%) Hungary1 ( 3%) Luxemburg1 ( 3%) Luxemburg1 ( 3%) Serbia1 ( 3%) Serbia1 ( 3%) Slovenia1 ( 3%) Slovenia1 ( 3%) _______________________________ _______________________________ response rate = 32% (39/123)

number of dialysis patients per centre No. of centres responding28 No. of centres responding28 Mean (SD)196 (245) Mean (SD)196 (245) Median113 Median113 Range Range

transplant activity ____________________________________________________________________________________ ____________________________________________________________________________________ ____________________________________________________________________________________ Transplant Carried OutYes33 (85%) Transplant Carried OutYes33 (85%) No1 ( 3%) No1 ( 3%) No Answer5 (13%) No Answer5 (13%) Number of Transplant Patients FollowedUp Number of centres responding 38 Number of Transplant Patients FollowedUp Number of centres responding 38 Mean (SD)512 (512) Mean (SD)512 (512) Median340 Median340 Range35->2000 Range35->2000 % Transplant Patients Using Epo Number of centres responding 28 % Transplant Patients Using Epo Number of centres responding 28 Mean (SD) 20 (16) Mean (SD) 20 (16) Median 14 Median 14 Range 2-71 Range 2-71 ____________________________________________________________________________________ ____________________________________________________________________________________

monitoring blood count/anaemia ___________________________________________________ Person Monitoring Blood Counts in Person Monitoring Blood Counts in Transplant Patients Transplant Patients ___________________________________________________ ___________________________________________________ Doctor37 (95%) Transplant Nurse11 (28%) Nephrology Nurse3 ( 8%) Other3 ( 8%) Identified Person Monitoring Anaemia 12 (31%)

percentage of transplant patients with Hb <11 g/dl _________________________________________ _________________________________________ Number of centres responding36 Number of centres responding36 Mean (SD)16 (12) Mean (SD)16 (12) Median15 Median15 Range2-60 Range2-60 _________________________________________ _________________________________________

parameters used to determine cause of anaemia _________________________________________ _________________________________________ Parameter n (%) Parameter n (%) _________________________________________ _________________________________________ Hb38 (97%) Hb38 (97%) Ferritin33 (85%) Ferritin33 (85%) Transferrin25 (64%) Transferrin25 (64%) PTH25 (64%) PTH25 (64%) Folate24 (62%) Folate24 (62%) Reticulocytes22 (56%) Reticulocytes22 (56%) Vitamin B1222 (56%) Vitamin B1222 (56%) Red Cell Indices18 (46%) Red Cell Indices18 (46%) % Hypochromic Red Cells14 (36%) % Hypochromic Red Cells14 (36%) _________________________________________ _________________________________________

Hb threshold to start epo _________________________________________ Hb (g/dl) _________________________________________ _________________________________________ No threshold given ( 3%) 9.02 ( 7%) (31%) (24%) (24%) ( 7%) ( 3%) Mean (SD)10.4 (0.8) Median10.5 Range _________________________________________ _________________________________________

Hb threshold to start epo %

Hb at which epo commences  All questionnaires: range g/dL variation within countries- Germany (most number of responses from single country): range g/dL variation within countries- Germany (most number of responses from single country): range g/dL

 13,347 pts covered by survey  1,726 patients were anaemic (16%)  PTA range 2-60%

% anaemic transplant pts by centre %

protocols for anaemia management ___________________________________________________________ Parametern(%) ___________________________________________________________ Use of Epo29 (74%) IV Iron Administration27 (69%) Immunosuppression Review25 (64%) Modification of Other Drugs21 (54%) Blood Transfusion13 (33%) Folate1 ( 3%) Would Find Algorithm Useful30 (88%) ___________________________________________________________

% anaemia vs nurse or no nurse monitor nurse no nurse Range 3-60% Mean 20.8 Median 17.5 Range 2-40% Mean 14.7 Median 12

%pts on epo vs %pts anaemic each centre

%PTA vs epo threshold

%anaemia vs use of algorithm NO YES

summary  Survey sent to 123 transplant centers in 13 countries. results show wide variance:  1,726 of 13,347 recipients were diagnosed as being anaemic (average: 16%; range: 2-60%).  working protocols varied with respect to the laboratory tests upon which anaemia was diagnosed, who monitored and/or treated anaemia, Hb threshold for treatment, and treatment.

Reticulocye count 1 x for blood loss/Haemolysis Hb < 11 g/dl on 2 successive occasions Investigate cause of Anaemia Antiproliferatives mTOR inhibitors ACEI/ARB Refer to Doctor Assess Fe" status eGFR Cockroft Gault/MDRD < 30 ml/min GFR Eligible for EPO Follow A then B Check B/P < 125/80 mm Hg > 125/80 mm Hg Refer to Dr for B/P Doctor to set Hb Target & prescribe EPO Response Maintenance Dose Ferritin > 150 ng/dl Check CRP Check B12 Check red cell folate Check PTH Discuss with Dr Ferritin < 200 ng/dl Give IV iron Reassess Fe " status Ferritin > 200 ng/dl + Hb < 11 g/dl Refer to Dr Ferritin 200 < ng/dl Refer to Dr Yes No + ve – ve > 20 > 200 Normal < 10 > 10 Low <200 ↑ (70x10 l) B A Algorithm For Anaemia Management In Transplant Patients

Causes of PTA  Immunosuppressants  Infection  Antiviral drugs  ACE-I, ARBs  Attitude!  CKD: funding, renal function, iron, folate, PTH

conclusion  PTA is common: inadequate approach in many centres  regular screening and evaluation of contributing factors is recommended  EDTNA/ERCA pocket guide & algorithm, slide set

additional comments - highlighted the need for dedicated person to monitor Hb -algorithm for Doctors not Nurses -epo only funded reliably for dialysis pts. Protocol is for CRF pts -tx centre not certified for epo use so nephrology centre has to prescribe epo or iron -protocol is for all patients. Useful to have alg. but may not be followed by Drs

%pts on epo vs %pts anaemic each centre

% anaemia vs nurse or no nurse monitor

%pts on epo vs %pts anaemic each centre